Prof. Stephan Jacob shares his thoughts about the prevention and management of T2DM and cardiometabolic disease.
AHA 2021 It is not clear yet what the effect of aspirin is on the risk of dementia in patients with T2DM. Prof. Armitage presents a study in which this was investigated using data of the ASCEND trial.
AHA 2021 Using data of the ASCEND trial, this study showed that there was no significant effect of aspirin on dementia outcomes compared to placebo in patients with T2DM.
Managing patients with diabetes requires a team approach of physicians in primary care, nephrologists, cardiologists and diabetologists. In this e-learning course, the discussants present a case of a patient with diabetes and comorbidities that shows the complexity of management of such a patient.
Watch the entire symposium on teaming up to tackle cardiorenal risk in diabetes - The role of SGLT2i: How to overcome clinical inertia?
As part of a series on tackling cardiorenal risk in diabetes, prof. Davies and prof. Marx state that current use of SGLT2 inhibitors is low and discuss how to overcome this.
This presentation by prof. Marx is the second part of a series on tackling cardiorenal risk in patients with diabetes. He provides an overview of clinical trials with SGLT2 inhibitors and current recommendations in guidelines.
Watch the first part of a series on tackling cardiorenal risk in patients with diabetes by teaming up. Prof. Davies introduces the topic and presents a case.
View this accredited e-learning program with a focus on heart failure at our partner website ReachMD, a leading online learning platform for physicians and other healthcare professionals
EASD 2021 Cardiac adipose tissue measured by CT was reduced by treatment with liraglutide compared to placebo in patients with T2DM, but this reduction was dependent on changes in weight loss.
EASD 2021 This secondary analysis of the DAPA-CKD trial showed that the efficacy and safety of dapagliflozin on kidney and CV outcomes was consistent across subgroups of baseline albuminuria in patients with CKD, with and without T2DM.
EASD 2021 There is a wide distribution of 10-year and lifetime CV risk in diabetes patients with and without a history of CVD. Use of SGLT2 inhibitors and GLP-1RAs was low in all groups.